A JAMA Network Open article titled "Service Outcomes for Germline Test Delivery for Patients With Metastatic Prostate Cancer" by Maren T. Scheuner, MD, MPH@1, Katherine J. Hoggatt, PhD@2, Paloma Sales, PhD@3; et al. Published February 27, 2026.

Embedded and full mainstream #GermlineTesting models for patients with #MetastaticProstateCancer in the VA improved effectiveness, efficiency, and timeliness compared with the traditional genetic consultation approach.

ja.ma/46xZtxw

Today's cancer #wordoftheday is:

#MetastaticProstateCancer — Prostate cancer that has spread beyond the prostate to areas like the bones, lymph nodes, liver, or lungs. It often signals a more advanced stage of disease and may cause new symptoms or require different treatments.

Pfizer's Talzenna therapy accepted for use within NHS Scotland - PharmaTimes Scottish Medicines Consortium approves new option for mCRPC patients

#prostatecancer #Pfizer #Talzenna #talazoparib #Talzennatherapy #NHSScotland #ScottishMedicinesConsortium #SMCapprovel #mCRPCpatients #metastaticcastrationresistantprostatecancer #mCRPC #polyADPribosepolymeraseinhibitor #PARPinhibitor #metastaticprostatecancer
pharmatimes.com/news/pfizers...

NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC - OncoDaily NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC / cancer, darolutamide, docetaxel, Metastatic Hormone-sensitive Prostate Cancer,

NCODA’s PQI simplifies the use of Darolutamide with Docetaxel for mHSPC

oncodaily.com/insight/201195

#Cancer #Darolutamide #Docetaxel #ProstateCancer #MetastaticProstateCancer #mHSPC #NCODA #NCODAPQI #OncoDaily #Oncology #PQIinAction